Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation

被引:21
|
作者
Bastidas-Mora, Gabriela [1 ,2 ]
Bea, Silvia [1 ,2 ,3 ,4 ,5 ]
Navarro, Alba [3 ,5 ]
Gine, Eva [1 ,2 ,3 ,5 ]
Costa, Dolors [1 ,2 ,3 ,5 ]
Delgado, Julio [1 ,2 ,3 ,5 ]
Baumann, Tycho [1 ,2 ,5 ,6 ]
Magnano, Laura [1 ,2 ,3 ]
Rivas-Delgado, Alfredo [1 ,2 ,3 ]
Villamor, Neus [1 ,2 ,3 ,5 ]
Colomer, Dolors [1 ,2 ,3 ,4 ,5 ]
Lopez-Guerra, Monica [1 ,2 ,3 ,5 ]
Rozman, Maria [1 ,2 ,3 ]
Balague, Olga [1 ,2 ,3 ,5 ]
Martinez, Daniel [1 ,2 ,5 ]
Baptista, Maria Joao [7 ]
Escoda, Lourdes [8 ]
Alcoceba, Miguel [5 ,9 ]
Blanes, Margarita [10 ]
Climent, Fina [11 ]
Campo, Elias [1 ,2 ,3 ,4 ,5 ]
Wotherspoon, Andrew [12 ]
Lopez-Guillermo, Armando [1 ,2 ,3 ,4 ,5 ]
Matutes, Estella [1 ,2 ]
机构
[1] Hosp Clin Barcelona, Hematol Dept, Barcelona, Spain
[2] Hosp Clin Barcelona, Hematopathol Sect, Pathol Dept, Barcelona, Spain
[3] Inst Invest Biomed August Pi i Sunyer IDIBAP, Barcelona, Spain
[4] Univ Barcelona, Barcelona, Spain
[5] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
[6] Hosp 12 Octubre, Serv Hematol, Madrid, Spain
[7] Josep Carreras Leukaemia Res Inst IJC, ICO Hosp Germans Trias & Pujol, Barcelona, Spain
[8] ICO Hosp Joan XXIII, Tarragona, Spain
[9] Univ Hosp Salamanca HUS IBSAL, Dept Hematol, Canc Res Inst Salamanca IBMCC USAL CSIC, Salamanca, Spain
[10] Hosp Gen Univ Elda, Alicante, Spain
[11] Hosp Univ Bellvitge IDIBELL, Dept Pathol, Barcelona, Barcelona, Spain
[12] Royal Marsden NHS Fdn Trust, London, England
关键词
splenic marginal zone lymphoma; histological transformation; complex karyotype; prognostic factors; survival; B-CELL LYMPHOMA; FOLLICULAR LYMPHOMA; VILLOUS LYMPHOCYTES; RESPONSE CRITERIA; RISK; RITUXIMAB; SURVIVAL; SPLENECTOMY; MULTICENTER; SERIES;
D O I
10.1111/bjh.17815
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We describe 36 patients with splenic marginal zone lymphoma (SMZL) with transformation (SMZL-T), including 15 from a series of 84 patients with SMZL diagnosed at the Hospital Clinic of Barcelona (HCB) and 21 diagnosed with SMZL-T in other centres. In the HCB cohort, the cumulative incidence of transformation at 5 years was 15%. Predictors for transformation were cytopenias, hypoalbuminaemia, complex karyotype (CK) and both the Intergruppo Italiano Linfomi (ILL) and simplified Haemoglobin, Platelet count, lactate dehydrogenase (LDH) and extrahilar Lymphadenopathy (HPLL)/ABC scores (P < 0 center dot 05). The only independent predictor for transformation in multivariate analysis was CK [hazard ratio (HR) 4 center dot 025, P = 0 center dot 05]. Patients with SMZL-T had a significantly higher risk of death than the remainder (HR 3 center dot 89, P < 0 center dot 001). Of the 36 patients with SMZL-T, one developed Hodgkin lymphoma and 35 a diffuse large B-cell lymphoma, 71% with a non-germinal centre phenotype. The main features were B symptoms, lymphadenopathy, and high serum LDH. CK was observed in 12/22 (55%) SMZL-T and fluorescence in situ hybridisation detected abnormalities of MYC proto-oncogene, basic helix-loop-helix transcription factor (MYC), B-cell leukaemia/lymphoma 2 (BCL2) and/or BCL6 in six of 14 (43%). In all, 21 patients received immunochemotherapy, six chemotherapy, one radiotherapy and three splenectomy. The complete response (CR) rate was 61% and the median survival from transformation was 4 center dot 92 years. Predictors for a worse survival in multivariate analysis were high-risk International Prognostic Index (HR 5 center dot 294, P = 0 center dot 016) and lack of CR (HR 2 center dot 67, P < 0 center dot 001).
引用
收藏
页码:146 / 155
页数:10
相关论文
共 50 条
  • [21] Hereditary ovarian carcinomas: clinico-biological features and treatment
    Floquet, Anne
    Stoeckle, Eberhard
    Croce, Sabrina
    Longy, Michel
    Mc Grogan, Gaetan
    Barouk, Emmanuelle
    Bubien, Virginie
    Garbay, Delphine
    Joly, Eglantine
    Guyon, Frederic
    BULLETIN DU CANCER, 2014, 101 (02) : 167 - 174
  • [22] Comparison of immunohistochemical staining of splenic marginal zone hyperplasia and splenic marginal zone lymphoma
    Fillman, EP
    Burton, MP
    Ehsan, A
    Neuhauser, TS
    LABORATORY INVESTIGATION, 2003, 83 (01) : 232A - 232A
  • [23] Large B-cell lymphoma transformation of splenic marginal zone lymphoma.
    Mollejo, M
    Mateo, M
    Camacho, F
    Hernández, JM
    Santonja, C
    Piris, MA
    MODERN PATHOLOGY, 2001, 14 (01) : 173A - 173A
  • [24] -Large B-cell lymphoma transformation of splenic marginal zone lymphoma.
    Mollejo, M
    Mateo, M
    Camacho, F
    Hernández, JM
    Santonja, C
    Piris, MA
    LABORATORY INVESTIGATION, 2001, 81 (01) : 173A - 173A
  • [25] Comparison of immunohistochemical staining of splenic marginal zone hyperplasia and splenic marginal zone lymphoma
    Fillman, EP
    Burton, MP
    Ehsan, A
    Neuhauser, TS
    MODERN PATHOLOGY, 2003, 16 (01) : 232A - 232A
  • [26] TREATMENT OF SPLENIC MARGINAL ZONE LYMPHOMA
    Julhakyan, H.
    Grjimolovskiy, A.
    Karagulyan, S.
    Magomedova, A.
    Kremenetskaya, A.
    Kravchenko, S.
    Obukhova, T.
    Kaplanskaya, I.
    Samoylova, R.
    Vorobjev, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 622 - 622
  • [27] SPLENIC MARGINAL ZONE CELL LYMPHOMA
    SCHMID, C
    KIRKHAM, N
    DISS, T
    ISAACSON, PG
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1992, 16 (05) : 455 - 466
  • [28] A CASE WITH SPLENIC MARGINAL ZONE LYMPHOMA
    Cagliyan, G. Akgun
    LEUKEMIA RESEARCH, 2016, 49 : S34 - S34
  • [29] Treatment of splenic marginal zone lymphoma
    Kalpadakis, Christina
    Pangalis, Gerassimos A.
    Angelopoulou, Maria K.
    Vassilakopoulos, Theodoros P.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2017, 30 (1-2) : 139 - 148
  • [30] RISK OF HISTOLOGIC TRANSFORMATION (HT) IN SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) PATIENTS TREATED WITH RITUXIMAB
    Kalpadakis, C.
    Pangalis, G.
    Sachanas, S.
    Vassilakopoulos, T.
    Rondogianni, D.
    Dimitrakopoulou, A.
    Koulieris, E.
    Moschogiannis, M.
    Yiakoumis, X.
    Psyllaki, M.
    Tsirkinidis, P.
    Papadaki, H.
    Panayiotidis, P.
    Angelopoulou, M.
    HAEMATOLOGICA, 2016, 101 : 754 - 754